100 related articles for article (PubMed ID: 22063461)
1. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review.
Diaz-Padilla I; Amir E; Marsh S; Liu G; Mackay H
Gynecol Oncol; 2012 Feb; 124(2):354-65. PubMed ID: 22063461
[TBL] [Abstract][Full Text] [Related]
2. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
3. Associations of the glutathione S-transferase P1 Ile105Val genetic polymorphism with gynecological cancer susceptibility: a meta-analysis.
Zhao E; Hu K; Zhao Y
Oncotarget; 2017 Jun; 8(25):41734-41739. PubMed ID: 28410197
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic and germline prognostic markers of lung cancer.
Horgan AM; Yang B; Azad AK; Amir E; John T; Cescon DW; Wheatley-Price P; Hung RJ; Shepherd FA; Liu G
J Thorac Oncol; 2011 Feb; 6(2):296-304. PubMed ID: 21206385
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review.
Schutte T; Embaby A; Steeghs N; van der Mierden S; van Driel W; Rijlaarsdam M; Huitema A; Opdam F
Cancer Treat Rev; 2023 Apr; 115():102531. PubMed ID: 36893690
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
[TBL] [Abstract][Full Text] [Related]
7. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
Curigliano G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
[TBL] [Abstract][Full Text] [Related]
9. Follow-up routines in gynecological cancer - time for a change?
Vistad I; Moy BW; Salvesen HB; Liavaag AH
Acta Obstet Gynecol Scand; 2011 Jul; 90(7):707-18. PubMed ID: 21382018
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers and molecular biological markers in gynecologic malignancies.
Geisler JP; Geisler HE
Curr Opin Obstet Gynecol; 2001 Feb; 13(1):31-9. PubMed ID: 11176230
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).
Arians N; Foerster R; Rom J; Uhl M; Roeder F; Debus J; Lindel K
Radiat Oncol; 2016 Mar; 11():44. PubMed ID: 26988089
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families.
Auranen A; Joutsiniemi T
Acta Obstet Gynecol Scand; 2011 May; 90(5):437-44. PubMed ID: 21306348
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies.
Davidson B
Virchows Arch; 2018 Oct; 473(4):395-403. PubMed ID: 30145616
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta-analysis and trial sequential analysis.
Cao H; Gong Y; Wang Y
Int J Cancer; 2022 Dec; 151(11):1997-2003. PubMed ID: 35723079
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA and gynecologic cancers.
Kanekura K; Nishi H; Isaka K; Kuroda M
J Obstet Gynaecol Res; 2016 Jun; 42(6):612-7. PubMed ID: 27098274
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs in gynecological cancers: Small molecules with big implications.
Srivastava SK; Ahmad A; Zubair H; Miree O; Singh S; Rocconi RP; Scalici J; Singh AP
Cancer Lett; 2017 Oct; 407():123-138. PubMed ID: 28549791
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
